| Company Name: |
Biolab Reagents Gold |
| Tel: |
027-65279366 18108604356 |
| Email: |
products@biolabreagent.com |
| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
|
| | Monoclonal antibody 6B1 igg4 Basic information |
| Product Name: | Monoclonal antibody 6B1 igg4 | | Synonyms: | Cat-152;Human igg-4 anti-tgfb2 monoclonal antibody;Human igg4 anti-transforming growth factor-beta 2 monoclonal antibody;Lerdelimumab [inn];Monoclonal antibody 6B1 igg4;Research Grade Lerdelimumab;Lerdelimumab | | CAS: | 285985-06-0 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Monoclonal antibody 6B1 igg4 Structure]() |
| | Monoclonal antibody 6B1 igg4 Chemical Properties |
| | Monoclonal antibody 6B1 igg4 Usage And Synthesis |
| Uses | Lerdelimumab (CAT-152) is an IgG4 human anti-TGF-β2 recombinant monoclonal antibody. Lerdelimumab can be used as an anti-scarring agent for glaucoma research[1][2]. | | in vivo | Lerdelimumab (100 μL, 1 mg/mL; subconjunctival injection; on days 2, 3, 4, 7, 9, 11 and 14 after surgery) significantly improves glaucoma surgical outcome and reduces the risk of corneal side effects[1]. | | References | [1] Mead AL, et al. Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Invest Ophthalmol Vis Sci. 2003 Aug;44(8):3394-401. DOI:10.1167/iovs.02-0978
[2] Wormstone IM, et al. TGF-beta2-induced matrix modification and cell transdifferentiation in the human lens capsular bag. Invest Ophthalmol Vis Sci. PMID:12091431 |
| | Monoclonal antibody 6B1 igg4 Preparation Products And Raw materials |
|